Ruti Aga's six-year ban: two years for the substance, four for the forged prescription

The Athletics Integrity Unit's statement landed on Thursday, and the first figure the eye catches is six — a six-year ban. For Ruti Aga, the Ethiopian marathoner, that number is final. The information that matters here sits elsewhere. It sits in the fact that methylprednisolone, the substance at the centre of the case, is entirely legal out of competition. On the WADA Prohibited List it is an S9 glucocorticoid, not an anabolic steroid, and S9 applies in-competition only: a dose taken by injection, orally or rectally that is still present in a sample on race day becomes a violation, and the same dose taken a week earlier does not. A therapeutic knee injection, correctly timed, is lawful. The notebook knew before I did — I just kept writing.

Aga is 32, and the record says this was no marginal name. She won the 2026 Tokyo Marathon; she was second in Berlin in 2026 in 2:18:34; she has three second-place finishes at World Marathon Majors. This is the 2:18–2:20 class — close enough to the world record to be relevant, consistent enough at the majors to be seeded. In March she won a half marathon in China, and the sample from that race returned methylprednisolone. The AIU statement carries two elements: a presence violation and tampering. The provisional suspension ran from 10 September, and the ban is dated from the same day.

The race time, the field depth, the year of the race and the scope of the disqualification are all absent from what is available. A reporter's first duty is to say what is not known. So I will not make a claim about Aga's form. One inference I will make: an AIU sample in China exists only if that was a World Athletics Label-tier race with an elite women's field and a testing operation attached.

Start with the arithmetic. Two years for presence, four for tampering — six in total. The two-year figure tells us the panel treated the substance as specified and found no proven intent; the Code's entry point for such cases is four years, which drops to two absent intent. Four years is the standard tampering sanction. The real story is that the documents built this six-year ban, not the drug.

A defence existed, and it was technically sound. Intra-articular or peri-articular methylprednisolone for knee synovitis is ordinary sports medicine in distance runners. With genuine records, with the date and route of treatment documented, the argument becomes about why residue was still present on race day — and that argument has room for no-fault or reduced fault at the bottom end. The sanction could have run anywhere from zero to a short suspension. What happened is the inverse: a prescription was manufactured, and the one route that could have worked was closed.

The prescription story has the shape of that Kalinga mixed zone — a small piece of paper that gets checked in three places. One, the doctor who issued it was a family member, not a registered practitioner. Two, the clinic on the letterhead did not exist. Three, the individual claimed to have used an old prescription pad from a former workplace, and that clinic stated plainly that no such pad was ever theirs. Three independent verification failures. The tampering charge rests on more than paper; statements given during the interview are part of the record.

The knee is the root cause. Chronic knee pathology is the most common load-bearing failure in marathoners, and the pressure on an injured athlete is directly financial — appearance fees, an agent's commission, a sponsor's expectations. A glucocorticoid is the cheapest, most available tool for masking that pain. The question is not why the drug was taken. The question is why no credentialed team physician was standing anywhere near it.

Hosting elite athlete introductions at the Mumbai Marathon, I used to note one thing: the big agency-managed camps arrive with a physio and a doctor, the smaller ones with a coach and a phone. There is no visible TUE infrastructure in Aga's case. An athlete with a documented injury and a documented treatment either holds a TUE or observes WADA's route-specific washout. Neither happened here. Paperwork happened.

China's label-race circuit is the income tier between majors for East African marathoners — decent appearance fees, low profile, low risk. It is now also the AIU's highest-yield testing ground. Two economies are colliding inside the same race: the fee economy and the testing economy. Somewhere between the roar and the rent, someone is deciding.

Now the part that deserves argument. A large strand of English-language coverage called methylprednisolone a prohibited steroid and reported that WADA classifies it as performance enhancing. That is technically wrong, and the error is not neutral. It files Aga's case alongside anabolic-steroid cases, where comparison becomes easy and the argument stops there. Glucocorticoids have no established endurance benefit; they reduce inflammation and suppress pain. What the severity of the sanction is measured against depends on the class of the substance, and the class was misreported.

Second, proportion. Six years for a drug with no proven endurance benefit will be cited as evidence of AIU rigour and, by others, as evidence of uneven enforcement against African road runners. The honest reading is narrower: four years for tampering is written into the Code, and tampering was proven. The debate belongs on the documents, not on the drug.

Third, what the statement leaves out. A family member was named. Whether an agent, a manager or whoever entered her for that Chinese race was investigated is not stated anywhere. An athlete without a credentialed doctor does not fabricate a prescription alone; someone advises, someone accepts. And Ethiopia's women's marathon depth is such that the removal of a 32-year-old 2:18 performer changes nothing in national selection. This is a governance story, not a competition story.

The CAS appeal window is typically about 21 days from the reasoned decision, and a document-based finding is hard to overturn. A return at 38 is practically closed inside Ethiopian selection depth, and the March result and its prize money should be read as void even though the statement does not spell out the scope. I don't chase the story. I stand where it usually walks. The next time a 2:18 marathoner with a sore knee lands in China in March, whose number will be in her phone?